State insurance commissioners earlier this month agreed to set up a subgroup to explore the possibly of creating a new model law for states that want to increase their oversight of pharmaceutical benefit managers. The move comes amid a heated national debate over the role of PBMs in rising drug prices, with the Trump administration looking to both restrict the middlemen's role in Medicare Part D and increase their role in Medicare Part B . As the state insurance regulators...